Abstract: A system, method, and program product are provided that receives a plurality of layout configuration selections from a user editing a layout configuration is provided. The layout configuration includes layout locations and each of the layout locations includes components, and each of the components includes attributes. The system, method, and program product receives attribute selections and trigger values from the user. The layout configuration, including the attribute selections and the trigger values, are stored in a nonvolatile storage area along with other layout configurations. When a request is received, the triggers stored in the nonvolatile storage area are compared to the request and one of the layout configurations is selected based on the comparison.

Abstract: An aircraft attitude control configuration enables control surfaces to provide attitude control for an aircraft at hover or low air speed conditions. The aircraft attitude control configuration includes a thruster mounted to an aircraft for thrusting air, a first control surface kinematically coupled to the aircraft at a position downstream of the thruster, and a second control surface kinematically coupled to the aircraft at a position downstream of the thruster, the second control surface being differentially movable with respect to the first control surface such that a portion of the thrusted air from the thruster generates a first vector force on the first control surface and another portion of the thrusted air generates a second vector force on the second control surface, so that the first and the second vector forces provide a net roll moment about the Y-Roll axis.

Abstract: A tamper indicating security device has a base and a separate cover which is snap engaged in a recess in the base with adjacent surfaces of the base and cover receiving at least part of a label having a signature area which extends across a junction between the base and cover surfaces. An elongate, flexible member has a first end secured to the base and a second free end for extending through eyelets of a closure of an item to be protected. Opposing inner faces of the cover and recess together form a trapper formation for receiving and trapping the free end of the elongate member so as to secure the security device across a closure. The free end of the elongate member cannot be released from the trapper formations without removing the cover and thereby destroying the label.

Abstract: Antibacterial 3-aminoquinazolin-2,4-diones have formula (I) wherein: R1 and R3 include alkyl, alkenyl, cycloalkyl, aryl, hetero-cyclic, and heteroaryl; R5, R6, and R8 include H, alkyl, alkoxy, halo, NO2, CN, NH2, alkyl and dialkylamino; R7 includes hydrogen, alkyl, cycloalkyl, hetero-cyclic, fused heterocyclic, aryl and fused aryl; J and K are C or N; and pharmaceutically acceptable salts thereof.

Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.

Abstract: The compound 1-(indole-6-carbonyl-D-phenylglycinyl)-4-(1-methylpiperidin-4-yl)piperazine and physiologically-tolerable salts thereof are factor Xa inhibitors useful for the treatment of thrombotic disorders.

Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.

Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.

Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.

Abstract: This invention is designed to attract wildlife by simulating a real food product that attracts them. Currently, there are other methods of attracting wildlife, but this invention allows the user to attract wildlife without using real food, as it is illegal in some states to use real food as a wildlife attractant. Some users may find it beneficial because unlike real food, it will not decompose, and cannot be ingested; therefore it could last indefinitely and be used over and over again. This would make this a cost effective means of attracting wildlife.

Abstract: Compounds of formula (I) 1

Abstract: Compounds of formula (I) 1

Abstract: Compounds of formula (I) 1

Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, factor Xa and are useful in the treatment of cardiovascular disorders.

Abstract: Compounds of formula (I) 1

Abstract: The present invention discloses novel substituted aryl alkylamine compounds of Formula (I) or pharmaceutically acceptable salts thereof which have selective histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such cyclic amines as well as methods of using them to treat obesity and other histamine H3 receptor-related diseases.

Abstract: The invention provides novel processes for making ethyl-4-cyano-3-hydroxybutyrate, e.g., (R)-ethyl 4-cyano-3-hydroxybutyric acid, and 4-cyano-3-hydroxybutyric acid. The invention provides protocols for making and 4-cyano-3-hydroxybutyric acid and ethyl-4-cyano-3-hydroxybutyrate by whole cell processes, cell lysate processes, “one pot processes” and “multi-pot” processes using a variety of parameters.

Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.

Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.

Abstract: The invention relates to serine protease inhibitor compounds of formula (I) where R1 is hydrogen, halo, cyano, nitro or hydroxyl, amino, alkoxy, alkyl, aminoalkyl, hydroxyalkyl, thiol, alkylthio, aminosulphonyl, alkoxyalkyl, alkoxycarbonyl, acyloxymethoxycarbonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl, cycloalkyl, amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, alkylsulphonamido, alkylaminosulphonyl, haloalkoxy and haloalkyl; R2 is hydrogen, halo, methyl, amino, hydroxy, or oxo; and R is X—X—Y(R7)—L—Lp(D)n; wherein each X independently is a C, N, O or S atom or a CO, CR1, C(R1)2 or NR1 group, at least one X being C, CO, CR1 or a C(R1)2 group; Y (the &agr;-atom) is a nitrogen atom or a CR1 group or Y and L taken together form a cyclic group; R7 is a lipophilic group selected from alkyl, alkenyl, mono- or bi-cycloalkyl, aryl, heteroaryl, mono- or bicycloalkylalkyl, mono- or bicycloalkylalkenyl, aralkyl, heteroaryl-alkyl